Evidence map›Paper›PMID 35246265›Full record

ArticlePilot and feasibility studies2022

The Sickle Cell Disease Functional Assessment (SCD-FA) tool: a feasibility pilot study.

Charity I Oyedeji, Katherine Hall, Alison Luciano, Miriam C Morey, John J Strouse

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Pilot and feasibility studies, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05714098 (Gerofit Exercise Intervention for Older Adults With Sickle Cell Disease), which is not on this map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05714098 nacompletednot on this mapstarted 2023, after this paper: background citation

Gerofit Exercise Intervention for Older Adults With Sickle Cell Disease (SICKLE-FIT Study)

TypeinterventionalSponsorDuke UniversityRan2023 to 2025Enrolled33ConditionsSickle Cell DiseaseArmsGerofit Exercise Program
3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Frailty phenotype in adults with sickle cell disease.The journals of gerontology. Series A, Biological sciences and medical sciences · 2026
    Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Charity I OyedejiDepartment of Medicine, Division of Hematology, Duke University School of Medicine, Durham, NC, USA. charity.oyedeji@duke.edu.ORCID http://orcid.org/0000-0001-5179-7142
Katherine HallDuke Claude D. Pepper Older Americans Independence Center, Durham, NC, USA.
Alison LucianoDuke Claude D. Pepper Older Americans Independence Center, Durham, NC, USA.
Miriam C MoreyDuke Claude D. Pepper Older Americans Independence Center, Durham, NC, USA.
John J StrouseDepartment of Medicine, Division of Hematology, Duke University School of Medicine, Durham, NC, USA.
Duke University · US

Funding

Resource Core 3 - Metabolomics CoreP30AG028716 · NIA · DUKE UNIVERSITY · PI Sarah B. Peskoe · 2006 to 2026
$24.6M
Research Project 3U54MD012530 · NIMHD · DUKE UNIVERSITY · PI JOHNSON, KIMBERLY S. · 2017 to 2022
$8.8M
american society of hematology Research Training Award for Fellowsduke center for research to advance healthcare equity (reach equity), which is supported by the national institute on minority health and health disparities U54MD012530duke claude d. pepper older americans independence center supported by the national institute of aging NIA P30AG028716NIA NIH HHS P30 AG028716NIMHD NIH HHS U54 MD012530
6 · The paper itself

Abstract

backgroundThe life expectancy for individuals with sickle cell disease (SCD) has greatly increased over the last 50 years. Adults with SCD experience multiple complications such as cardiopulmonary disease, strokes, and avascular necrosis that lead to limitations that geriatric populations often experience. There are no dedicated instruments to measure functional decline and functional age to determine risk of future adverse outcomes in older adults with SCD. The objective of this study was to assess the feasibility of performing the Sickle Cell Disease Functional Assessment (SCD-FA).

methodsWe enrolled 40 adults with SCD (20 younger adults aged 18-49 years as a comparison group and 20 older adults aged 50 years and older) in a single-center prospective cohort study. Participants were recruited from a comprehensive sickle cell clinic in an academic center in the southeastern United States. We included measures validated in an oncology geriatric assessment enriched with additional physical performance measures: usual gait speed, seated grip strength, Timed Up and Go, six-minute walk test, and 30-second chair stand. We also included an additional cognitive measure, which was the Montreal Cognitive Assessment, and additional patient-reported measures at the intersection of sickle cell disease and geriatrics. The primary outcome was the proportion completing the assessment. Secondary outcomes were the proportion consenting, duration of the assessment, acceptability, and adverse events.

resultsEighty percent (44/55) of individuals approached consented, 91% (40/44) completed the SCD-FA in its entirety, and the median duration was 89 min (IQR 80-98). There were no identified adverse events. On the acceptability survey, 95% (38/40) reported the length as appropriate, 2.5% (1/40) reported a question as upsetting, and 5% (2/40) reported portions as difficult. Exploratory analyses of physical function showed 63% (25/40) had a slow usual gait speed (< 1.2 m/s).

conclusionThe SCD-FA is feasible, acceptable, and safe and physical performance tests identified functional impairments in adults with SCD. These findings will inform the next phase of the study where we will assess the validity of the SCD-FA to predict patient-important outcomes in a larger sample of adults with SCD.

Indexed as

AgingFrailtyFunctional assessmentGait speedGeriatric assessmentGeriatricsOlder adultsSickle cell disease

Identifiers

PMID35246265
PMCPMC8895638
OpenAlexW4221110594

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.